
FDA resurrects Satsuma's nasal migraine treatment
More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi (formerly STS101) has been given the go-ahead by the agency. The drug – a new dry powder intranasal formulation of the well-established migraine …